Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.54 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.54 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.54 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribose (Furanose) SCHEMBL15814845 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL14349491 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL447758 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL16199379 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL24087736 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL66645 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL23017520 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL12878699 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL7618455 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Ribose (Furanose) SCHEMBL13135754 | 1.00 | LGALS1 (0.54) | LGALS1LGALS3LGALS9LGALS8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 974 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737469-A1 | NUCLEIC ACID CONJUGATES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Siran Biotechnology Co., Ltd. (CN) | 2026-05-06 | — | — | EP | claimed |
| US-12540323-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | Suzhou Ribo Life Science Co., Ltd. (CN) | 2026-02-03 | — | — | US | claimed |
| US-12496347-B2 | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-12-16 | — | — | US | claimed |
| US-12497622-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-12-16 | — | — | US | claimed |
| EP-4628583-A1 | BICYCLIC ABASIC NUCLEIC ACID ANALOGS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2025-10-08 | — | — | EP | claimed |
| US-12428642-B2 | Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-09-30 | — | — | US | claimed |
| WO-2025083315-A1 | OLIGONUCLEOTIDES OR ANALOGUES THEREOF FOR THE TREATMENT OF FUCHS ENDOTHELIAL CORNEAL DYSTROPHY | ARTHEX BIOTECH S.L. (ES) | 2025-04-24 | — | — | WO | claimed |
| EP-4527459-A2 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-03-26 | — | — | EP | claimed |
| EP-4518902-A1 | BRANCHED LINKER FOR ASIALOGLYCOPROTEIN RECEPTOR LIGANDS | Guangzhou Ribobio Co., Ltd. (CN) | 2025-03-12 | — | — | EP | claimed |
| EP-3732185-B1 | CONJUGATES AND PREPARATION AND USE THEREOF | SUZHOU RIBO LIFE SCIENCE CO LTD (CN) | 2025-02-26 | — | — | EP | claimed |
| EP-1144425-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2001-10-17 | — | — | EP | claimed |
| EP-0726274-B1 | G-cap stabilized oligonucleotides | AVENTIS PHARMA GMBH (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000042053-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES LIMITED (US) | 2000-07-20 | — | — | WO | claimed |
| EP-0979869-A1 | Short oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-16 | — | — | EP | claimed |
| US-6013639-A | MODIFYING END GROUPS; DIAGNOSIS, THERAPY CANCER, RESTENOSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-01-11 | — | — | US | claimed |
| EP-0668866-B1 | ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY COMPOUNDS: DERIVATIVES OF PENTOSE MONOSACCHARIDES | BOSTON LIFE SCIENCES INC (US) | 1997-07-30 | — | — | EP | claimed |
| EP-0777673-A2 | ALPHA-D-PENTOFURANOSIDE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND THEIR USE | Saischek, Jörn (AT) | 1997-06-11 | — | — | EP | claimed |
| WO-1996006103-A2 | α-D-PENTOFURANOSIDE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND THEIR USE | SAISCHEK JOERN (AT) | 1996-02-29 | — | — | WO | claimed |
| EP-0668866-A1 | ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY COMPOUNDS: DERIVATIVES OF PENTOSE MONOSACCHARIDES. | GREENWICH PHARMA (US) | 1995-08-30 | — | — | EP | claimed |
| WO-1994011381-A1 | ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY COMPOUNDS: DERIVATIVES OF PENTOSE MONOSACCHARIDES | GREENWICH PHARMACEUTICALS INCORPORATED (US) | 1994-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540323-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | PCSK9, APOB, NSUN2 | LGALS1 4012/4885LGALS3 4492/4885LGALS9 1560/4885 |
| US-12497622-B2 | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use | F13A1, F13B, F11 | LGALS1 4335/4885LGALS3 4315/4885LGALS9 2787/4885 |
| US-12428642-B2 | Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof | TEK, TIE1, IGF2BP3 | LGALS1 2526/4885LGALS3 1571/4885LGALS9 2157/4885 |
| US-12496347-B2 | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | APOB, PCSK9, APOL1 | LGALS1 2723/4885LGALS3 4255/4885LGALS9 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.